Global castrate resistant prostate cancer market growth is driven by rising prevalence of prostate cancer worldwide. Prostate cancer is one of the commonly occurring cancers among men. According to the data from American Cancer Society in 2020, around 191,930 new cases of prostate cancer were reported in the U.S. Once the cancer has metastasized and started growing despite medical or surgical therapy to reduce testosterone levels or block its action, it is termed as castrate resistant prostate cancer (CRPC). Currently available treatment options for CRPC include chemotherapy, immunotherapy, radiation therapy, and others. However, development of resistance remains a major challenge in effectively managing this advanced stage of prostate cancer. Ongoing research for novel drug targets and therapeutic approaches can overcome treatment resistance and improve patient outcomes in CRPC.
Market Dynamics:
Global castrate resistant prostate cancer market growth is driven by rising geriatric population susceptible to developing prostate cancer. According to the data from UN World Population Prospects 2019, the number of people aged 65 years or above is projected to grow from 703 million in 2019 to 1.5 billion in 2050 globally. Increasing awareness and screening rates have also augmented the early detection of prostate cancer, thus, driving the market growth. However, high treatment costs associated with immunotherapy and targeted therapy regimens can hamper the market growth. Ongoing research to develop novel mechanisms for overcoming drug resistance can offer promising opportunities for market players. Development of affordable biosimilars can reduce treatment costs.
Key Features of the Study:
Detailed Segmentation-
Table of Contents
*Browse 32 market data tables and 28 figures on "Castrate Resistant Prostate Cancer Market” -Global forecast to 2031
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients